Candida dubliniensis meningitis as delayed sequela of treated C. dubliniensis fungemia.
We present a case of Candida dubliniensis meningitis that developed 2 months after apparently successful treatment of an episode of C. dubliniensis candidemia in a heart-lung transplant recipient in Australia. This case highlights the importance of follow-up in patients with candidemia or disseminated infection, especially in immunosuppressed patients.
van Hal
Sebastian J
SJ
St. Vincent's Hospital, Darlinghurst, New South Wales, Australia. vanhal@gotalk.net.au
Stark
Damien
D
Harkness
John
J
Marriott
Deborah
D
D000935:Antifungal Agents / Q000627:therapeutic use; D002175:Candida / Q000145:classification / Q000302:isolation & purification*; D002177:Candidiasis / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D000077336:Caspofungin; D054714:Echinocandins / Q000627:therapeutic use; D015725:Fluconazole / Q000627:therapeutic use; D016469:Fungemia / Q000150:complications* / Q000188:drug therapy* / Q000382:microbiology; D016027:Heart Transplantation / Q000009:adverse effects; D006801:Humans; D055666:Lipopeptides; D008297:Male; D016921:Meningitis, Fungal / Q000382:microbiology*; D008875:Middle Aged
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D015725:Fluconazole; D000077336:Caspofungin